These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36153233)

  • 1. PET Imaging Using Gallium-68 (
    Duan H; Iagaru A
    PET Clin; 2022 Oct; 17(4):621-629. PubMed ID: 36153233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
    Baratto L; Song H; Duan H; Hatami N; Bagshaw HP; Buyyounouski M; Hancock S; Shah S; Srinivas S; Swift P; Moradi F; Davidzon G; Iagaru A
    J Nucl Med; 2021 Nov; 62(11):1545-1549. PubMed ID: 33674398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Evaluation of
    Minamimoto R; Sonni I; Hancock S; Vasanawala S; Loening A; Gambhir SS; Iagaru A
    J Nucl Med; 2018 May; 59(5):803-808. PubMed ID: 29084827
    [No Abstract]   [Full Text] [Related]  

  • 4. Correlation of
    Duan H; Baratto L; Fan RE; Soerensen SJC; Liang T; Chung BI; Thong AEC; Gill H; Kunder C; Stoyanova T; Rusu M; Loening AM; Ghanouni P; Davidzon GA; Moradi F; Sonn GA; Iagaru A
    J Nucl Med; 2022 Dec; 63(12):1829-1835. PubMed ID: 35552245
    [No Abstract]   [Full Text] [Related]  

  • 5. Dual-Modality Imaging of Prostate Cancer with a Fluorescent and Radiogallium-Labeled Gastrin-Releasing Peptide Receptor Antagonist.
    Zhang H; Desai P; Koike Y; Houghton J; Carlin S; Tandon N; Touijer K; Weber WA
    J Nucl Med; 2017 Jan; 58(1):29-35. PubMed ID: 27516447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
    Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Pilot Study of
    Duan H; Ghanouni P; Daniel B; Rosenberg J; Thong A; Kunder C; Aparici CM; Davidzon GA; Moradi F; Sonn GA; Iagaru A
    J Nucl Med; 2023 May; 64(5):744-750. PubMed ID: 36396456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
    Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
    J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pilot Study of
    Duan H; Ghanouni P; Daniel B; Rosenberg J; Davidzon GA; Aparici CM; Kunder C; Sonn GA; Iagaru A
    J Nucl Med; 2023 Apr; 64(4):592-597. PubMed ID: 36328488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Wang L; Zhang Z; Merkens H; Zeisler J; Zhang C; Roxin A; Tan R; Bénard F; Lin KS
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiometal Complexes as Pharmacokinetic Modifiers: A Potent
    Schreck MV; Burgard C; Schmidtke A; Hierlmeier I; Stemler T; Maus S; Rosar F; Jung M; Speicher A; Ezziddin S; Holland JP; Bartholomä MD
    Mol Pharm; 2023 Dec; 20(12):6463-6473. PubMed ID: 37978936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positron Emission Tomography Imaging of Prostate Cancer with Ga-68-Labeled Gastrin-Releasing Peptide Receptor Agonist BBN
    Cheng S; Lang L; Wang Z; Jacobson O; Yung B; Zhu G; Gu D; Ma Y; Zhu X; Niu G; Chen X
    Bioconjug Chem; 2018 Feb; 29(2):410-419. PubMed ID: 29254329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastrin-releasing Peptide Receptor Imaging in Breast Cancer Using the Receptor Antagonist (68)Ga-RM2 And PET.
    Stoykow C; Erbes T; Maecke HR; Bulla S; Bartholomä M; Mayer S; Drendel V; Bronsert P; Werner M; Gitsch G; Weber WA; Stickeler E; Meyer PT
    Theranostics; 2016; 6(10):1641-50. PubMed ID: 27446498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin.
    Sonni I; Baratto L; Iagaru A
    PET Clin; 2017 Apr; 12(2):159-171. PubMed ID: 28267450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET Probes for Preclinical Imaging of GRPR-Positive Prostate Cancer: Comparative Preclinical Study of [
    Kálmán-Szabó I; Szabó JP; Arató V; Dénes N; Opposits G; Jószai I; Kertész I; Képes Z; Fekete A; Szikra D; Hajdu I; Trencsényi G
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077458
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Rinne SS; Abouzayed A; Gagnon K; Tolmachev V; Orlova A
    Sci Rep; 2021 Feb; 11(1):3631. PubMed ID: 33574368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A heterodimeric [RGD-Glu-[(64)Cu-NO2A]-6-Ahx-RM2] αvβ3/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors.
    Durkan K; Jiang Z; Rold TL; Sieckman GL; Hoffman TJ; Bandari RP; Szczodroski AF; Liu L; Miao Y; Reynolds TS; Smith CJ
    Nucl Med Biol; 2014 Feb; 41(2):133-9. PubMed ID: 24480266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.
    Duan H; Davidzon GA; Moradi F; Liang T; Song H; Iagaru A
    Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):4087-4095. PubMed ID: 37555901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples.
    Morgat C; Schollhammer R; Macgrogan G; Barthe N; Vélasco V; Vimont D; Cazeau AL; Fernandez P; Hindié E
    PLoS One; 2019; 14(1):e0210905. PubMed ID: 30645633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.